Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tumor-specific immunoglobulin idiotype (Id) refers to the unique antigenic determinants found in the variable regions of immunoglobulins (antibodies) produced by malignant B cells, such as those in B-cell lymphomas and multiple myeloma. Each B-cell tumor expresses a clonal immunoglobulin with a distinct idiotype, which is not present on normal cells. These idiotypes are primarily determined by the complementarity-determining regions (CDRs) of the variable domains of both heavy and light chains, often shaped by somatic mutations. It can be recognized by both antibodies and T-cells, making it an effective target for immune-based therapies. Tumor-specific idiotypes have been exploited as targets for active immunotherapy, particularly in vaccine development.
Induction of humoral and cellular immune responses against tumor-specific idiotype; Antibody-mediated tumor cell killing.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-specific Immunoglobulin Idiotype (None).